Axel Hauschild

Kiel University — Germany

Medicine · Health Sciences

111h-index72.1kcitations816works11.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cutaneous Melanoma Detection and Management(369), Melanoma and MAPK Pathways(296), CAR-T cell therapy research(165), Nonmelanoma Skin Cancer Studies(153), Cancer Immunotherapy and Biomarkers(125)

Publications811 total

Étude randomisée de phase 3 comparant le cémiplimab adjuvant à un placebo et analyse des tumeurs primaires secondaires (TPS) dans le carcinome épidermoïde cutané à haut risque (CEC) : l’essai C-POST
Annales de Dermatologie et de Vénéréologie - FMC·2025
Clinical and Patient-Reported Outcomes (PROs) in C-POST: A Phase 3 Trial of Adjuvant Cemiplimab Versus Placebo for High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)
SKIN The Journal of Cutaneous Medicine·2025Open Access
Messages for ultraviolet‐radiation protection to fair‐skinned populations
Journal of the European Academy of Dermatology and Venereology·2025Open Access
Neues von der Jahrestagung der American Society of Clinical Oncology (ASCO). Positive Zulassungsstudie für adjuvante Therapie mit Cemiplimab für Patienten mit Hochrisiko‐Plattenepithelkarzinomen der Haut
JDDG Journal der Deutschen Dermatologischen Gesellschaft·2025Open Access
Baseline D-dimers as predictive marker of efficacy of cemiplimab treatment in cutaneous squamous cell carcinoma
European Journal of Cancer·2025· 3 citedOpen Access
Neoadjuvant intralesional targeted immunocytokines (daromun) in stage III melanoma
Annals of Oncology·2025· 4 citedOpen Access
Long-Term Follow-Up of Real-World Adjuvant Anti–PD-1 Checkpoint Inhibition and Targeted Therapy in Patients With Stage III Melanoma
Journal of Clinical Oncology·2025· 3 cited
Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell Carcinoma
New England Journal of Medicine·2025· 37 cited
Phase 3 trial of adjuvant cemiplimab (cemi) versus placebo (pbo) for high-risk cutaneous squamous cell carcinoma (CSCC).
Journal of Clinical Oncology·2025· 3 cited
A randomized phase 2 peri-operative (neoadjuvant plus adjuvant) study of fianlimab (anti–LAG-3) plus cemiplimab (anti–PD-1) versus anti–PD-1 alone in patients with resectable stage III and IV melanoma.
Journal of Clinical Oncology·2025· 2 cited
Adjuvante und neoadjuvante Therapie des Melanoms
DMW - Deutsche Medizinische Wochenschrift·2025
PREDICTION OF FIBROSIS IN PATIENTS WITH SEVERE AORTIC STENOSIS USING MACHINE LEARNING MODELS
Journal of the American College of Cardiology·2025Open Access
A0866 – A randomized, open-label, controlled clinical study to assess the digital health application INKA in the management of therapy refractory overactive bladder and mixed incontinence
European Urology·2025
Diagnosis and treatment of dermatofibrosarcoma protuberans. European interdisciplinary guideline – update 2024
European Journal of Cancer·2025· 14 citedOpen Access
Discordance, accuracy and reproducibility study of pathologists’ diagnosis of melanoma and melanocytic tumors
Nature Communications·2025· 12 citedOpen Access
Neonatal melanoma with lymph node metastasis
EJC Skin Cancer·2025Open Access
Baseline D-Dimers as Predictive Marker of Efficacy of Cemiplimab Treatment in Cutaneous Squamous Cell Carcinoma
SSRN Electronic Journal·2025Open Access
Neoadjuvant or perioperative therapy for melanoma metastasis in clinical practice: an international survey
The Lancet Oncology·2025· 3 cited
Neoadjuvant Cemiplimab for Stage II–IV Cutaneous Squamous Cell Carcinoma: 2-Year Follow-up and Biomarker Analyses
EJC Skin Cancer·2025Open Access
Diagnosis of Stage IV Melanoma
2024
page 1 of 41Next →

Frequent Co-authors

Dirk Schadendorf(27), Claus Garbe(25), Caroline Robert(18), Jean‐Jacques Grob(16), Reinhard Dummer(14), Célèste Lebbé(12), Vanna Chiarion‐Sileni(12), Jochen Utikal(11), James Larkin(10), Antoni Ribas(10), Carola Berking(10), Paolo A. Ascierto(9), Alexander M.M. Eggermont(9), Laurent Mortier(9), Georgina V. Long(9), John M. Kirkwood(8), Keith T. Flaherty(8), Jacob Schachter(8), Mario Mandalà(8), John B.A.G. Haanen(7)